RE: proactive investors piece20 Apr 2020 14:00
This bit says everything...
Peel Hunt upbeat
In a note to clients, analysts at Peel Hunt repeated their 'buy' rating on Genedrive shares and noted that the important feature of Genedrive’s 96 SARS-CoV-2 assay is that - when combined with Cytiva’s stabilisation technology - the assay lends itself to extreme, high-throughput, with the potential of manufacturing over 10,000 tests per hour in a 96-well, temperature-stable plate-format that could be transported globally without the requirement of refrigeration.
They said: "We share the company view that PCR testing for coronavirus will be required in huge numbers for the foreseeable future."
The analysts added: "As a reminder, this is only one of the two assay programmes that the company is pursuing/progressing (in relation to coronavirus) as announced on 25th March. Given the company’s focus on these assays/recent developments – and their exciting potential – we now put our TP/forecasts under review until the company has had chance to crystallise this opportunity."